Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.42 |
| ▸ | MEF2D | Q14814 | 3/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL853485 | 0.82 | NPSR1 (0.61) | TRPV1ALDH1A1KDM4EPKMSMN1; SMN2 | |
| SCHEMBL853486 | 0.82 | NPSR1 (0.61) | TRPV1ALDH1A1KDM4EPKMSMN1; SMN2 | |
| SCHEMBL15026335 | 0.79 | NPSR1 (0.49) | TRPV1ALDH1A1KDM4EPKMSMN1; SMN2 | |
| SCHEMBL14924014 | 0.79 | TRPV1 (0.47) | TRPV1ALDH1A1KDM4EPKMSMN1; SMN2 | |
| SCHEMBL16621540 | 0.78 | ALDH1A1 (0.38) | TRPV1ALDH1A1KDM4EPKMSMN1; SMN2 | |
| SCHEMBL3295979 | 0.78 | TTR (0.54) | TRPV1ALDH1A1KDM4EPKMSMN1; SMN2 | |
| SCHEMBL3295973 | 0.78 | TTR (0.54) | TRPV1ALDH1A1KDM4EPKMSMN1; SMN2 | |
| SCHEMBL6296644 | 0.78 | NFE2L2 (0.55) | ALDH1A1KDM4ESMN1; SMN2NPSR1MMP1 | |
| SCHEMBL18900602 | 0.78 | NPSR1 (0.65) | NPSR1CYP1A2CYP2C9HSD17B3 | |
| SCHEMBL6296643 | 0.78 | NFE2L2 (0.55) | ALDH1A1KDM4ESMN1; SMN2NPSR1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9757407-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | UNIV PRINCETON (US) | 2016-12-01 | — | — | US | disclosed |
| US-9029413-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-05-12 | — | — | US | disclosed |
| US-20130065850-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | TRPV1 4702/4885ALDH1A1 1469/4885KDM4E 2299/4885 |
| US-20130065850-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | TRPV1 4702/4885ALDH1A1 1469/4885KDM4E 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.